Key Points
Oct 2 (Reuters) - Takeda Pharmaceutical (4502.T) said on Monday it would be working with the U.S. health regulator towards a voluntary withdrawal of its lung cancer therapy in the country, after it failed to meet the main goal in a late-stage study...
The late-stage trial studied the safety and efficacy of Exkivity as a monotherapy versus a type of chemotherapy in patients with non-small cell lung cancer...
The therapy thus does not fulfill the confirmatory data requirements of the accelerated approval granted by the U.S. Food and Drug Administration nor the conditional marketing approvals granted in other countries, the Japan-based company said.. Takeda intends to similarly initiate voluntary withdrawal globally where the therapy is approved and is working with regulators in other countries where it is currently available on next steps...
The U.S. FDA had approved Exkivity in 2021 for patients with a specific gene mutation called EGFR Exon20 insertions in non-small cell lung cancer, whose disease has progressed on or after chemotherapy, based on results from an early- to mid-stage trial...
You might be interested in
Lung cancer pill cuts risk of death by half, says ‘thrilling’ study
04, Jun, 23Taking the drug osimertinib once a day after surgery reduces chance of patients dying by 51%, trials show
Cognitive behavioural therapy may help boost mental health of cancer survivors
24, Aug, 24Results of the study have important clinical ramifications, especially for supportive oncology professionals
AstraZeneca's Tagrisso slashes death risk in certain post-surgery lung cancer patients
06, Jun, 23AstraZeneca's lung cancer therapy, Tagrisso, cut the risk of death by more than half in patients with a certain form of lung cancer who were diagnosed early enough to have their tumour surgically removed, trial data showed.
All about India's 1st 'living drug' that uses patient's own genetically engineered cells to fight cancer
16, Oct, 23Patients already registering for CAR T-cell therapy, developed indigenously by ImmunoACT under the name NexCAR19. It will be used to treat leukemia & refractory or relapsed lymphoma.
Modifying chemotherapy treatment can improve lives of older people with cancer
22, Feb, 24The study shows that standard chemotherapy regimens can be harmful to older persons with cancer because of their other health conditions. | Health
Breakthrough cancer treatment to be available in India 1st time as CAR-T cell therapy gets DCGI nod
13, Oct, 23Therapy developed by IIT-Bombay spin-off company ImmunoACT approved for relapsed-refractory B-cell lymphoma, leukemia, to be available in around 20 govt & pvt hospitals across major cities.